Head to Head Analysis: Klotho Neurosciences (KLTO) and Its Rivals

Institutional and Insider Ownership

20.1% of Klotho Neurosciences shares are owned by institutional investors. Comparatively, 50.1% of shares of all “Biological products, except diagnostic” companies are owned by institutional investors. 26.7% of Klotho Neurosciences shares are owned by insiders. Comparatively, 15.2% of shares of all “Biological products, except diagnostic” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares Klotho Neurosciences and its peers gross revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Klotho Neurosciences	N/A	$1.35 million	-4.61
Klotho Neurosciences Competitors	$581.03 million	-$70.44 million	3.55

Klotho Neurosciences’ peers have higher revenue, but lower earnings than Klotho Neurosciences. Klotho Neurosciences is trading at a lower price-to-earnings ratio than its peers, indicating that it is currently more affordable than other companies in its industry.

Volatility and Risk

Klotho Neurosciences has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, Klotho Neurosciences’ peers have a beta of -4.59, meaning that their average share price is 559% less volatile than the S&P 500.

Profitability

This table compares Klotho Neurosciences and its peers’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Klotho Neurosciences	N/A	N/A	-25.89%
Klotho Neurosciences Competitors	-2,185.76%	-161.46%	-40.62%

Summary

Klotho Neurosciences beats its peers on 6 of the 9 factors compared.

Klotho Neurosciences Company Profile

Klotho Neurosciences, Inc., a biopharmaceutical company, develops therapies for neurological and age-related disorders, and specialty diagnostics. Its products include cell and gene therapies to mitigate age-related pathologies, such as dementia symptoms, and Alzheimer and neuromuscular diseases; biologics/biosimilars in the treatment of cancer; and melanocortin receptors. The company has a strategic partnership with Japan’s Okinawa Research Center for the research and development of Klotho gene therapy in enhancing longevity and reducing age-related diseases. The company was formerly known as Anew Medical, Inc. and changed its name to Klotho Neurosciences, Inc. in September 2024. Klotho Neurosciences, Inc. is based in Omaha, Nebraska.